Literature DB >> 8299230

Cell-mediated immunity in allopurinol-induced hypersensitivity.

G L Braden1, M J Warzynski, M Golightly, M Ballow.   

Abstract

Allopurinol may induce severe hypersensitivity characterized by hepatitis, interstitial nephritis, and skin rash. The mechanisms for this hypersensitivity syndrome are incompletely elucidated. Immunologic studies were performed on tissue and peripheral blood lymphocytes from a patient with allopurinol hypersensitivity. Immunohistochemistry was performed on sections of the liver biopsy utilizing monoclonal antibodies for T and B lymphocytes. Peripheral blood lymphocyte immunophenotyping by flow cytometry and peripheral blood lymphocyte stimulation studies with either allopurinol or oxypurinol measured as tritiated thymidine uptake were performed in the hypersensitive patient and compared to a group of six patients treated with allopurinol without hypersensitivity and eight normal control patients. Additional single- and dual-color immunophenotyping by flow cytometry of oxypurinol-stimulated lymphocytes was performed in the hypersensitive patient and compared to normal controls. The liver biopsy demonstrated predominantly a T lymphocyte infiltrate. The number of peripheral blood lymphocytes expressing activation antigens was significantly greater in the hypersensitive patient compared to that of both control groups. Lymphocytes from the hypersensitive patient were moderately stimulated by allopurinol and markedly stimulated by oxypurinol compared to both control groups. Oxypurinol-stimulated lymphocytes from the hypersensitive patient demonstrated enhanced expression of activation antigens compared to unstimulated lymphocytes from this patient and normal controls. These studies suggest that cell-mediated immunity directed toward allopurinol and more importantly to its oxypurinol metabolite is involved in the pathogenesis of allopurinol-induced hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8299230     DOI: 10.1006/clin.1994.1022

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  14 in total

1.  Drug Reaction, Eosinophilia and Systemic Symptoms (DRESS) syndrome secondary to allopurinol with early lymphadenopathy and symptom relapse.

Authors:  Rhiannon Turney; Jordan Peter Skittrall; Joseph Donovan; Daniel Agranoff
Journal:  BMJ Case Rep       Date:  2015-10-05

2.  Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions.

Authors:  Wen-Hung Chung; Ren-You Pan; Mu-Tzu Chu; See-Wen Chin; Yu-Lin Huang; Wei-Chi Wang; Jen-Yun Chang; Shuen-Iu Hung
Journal:  J Invest Dermatol       Date:  2015-05-06       Impact factor: 8.551

Review 3.  T cell-mediated hypersensitivity reactions to drugs.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Soren Buus; Imir Metushi; Bjoern Peters; Elizabeth Phillips
Journal:  Annu Rev Med       Date:  2014-10-27       Impact factor: 13.739

4.  Successful use of allopurinol in a patient on dialysis.

Authors:  Richard Osborne Day; Diluk Romesh Wijekoon Kannangara; James M Hayes; Timothy J Furlong
Journal:  BMJ Case Rep       Date:  2012-06-05

5.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

Review 6.  A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.

Authors:  Jeannie Chao; Robert Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 7.  Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

Authors:  Lisa K Stamp; Richard O Day; James Yun
Journal:  Nat Rev Rheumatol       Date:  2015-09-29       Impact factor: 20.543

Review 8.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.

Authors:  A G Fam
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.686

Review 10.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.